Molecular & Genetic Markers
MAPK/ERK pathway
The MAPK/ERK pathway is a cell growth-signaling system whose abnormal activation drives many pediatric low-grade gliomas.
In short: MAPK/ERK pathway
- It is a chain of signals that controls cell growth.
- Its abnormal activation drives many pediatric low-grade gliomas.
- BRAF changes are common ways it is activated.
- It can be targeted by BRAF and MEK inhibitor drugs.
What it is
The MAPK/ERK pathway is a system of signaling proteins inside cells that controls growth and division. Abnormal, continuous activation of this pathway drives many pediatric low-grade gliomas, often through changes in the BRAF gene.
Understanding MAPK/ERK pathway
Cells normally grow in response to controlled signals passed along the MAPK/ERK pathway. When a genetic change (such as a BRAF fusion or BRAF V600E mutation) locks this pathway "on," cells receive continuous growth signals, driving tumor formation. This pathway is the common thread linking many pediatric low-grade gliomas, even though the specific genetic changes vary. Its central role makes it a target for treatment: BRAF inhibitors (blocking BRAF directly) and MEK inhibitors (blocking a downstream step) can interrupt the pathway and treat these tumors, which is especially useful when surgery cannot fully remove the tumor. Understanding the MAPK/ERK pathway clarifies the growth-signaling system at the heart of many childhood gliomas and how it is targeted.
Why it matters
Understanding the MAPK/ERK pathway helps families see the common driver behind many pediatric low-grade gliomas — and why drugs that block this pathway (BRAF and MEK inhibitors) can treat these tumors.
Common questions
What is the MAPK/ERK pathway?
A signaling system that controls cell growth.
Why does it matter in gliomas?
Its abnormal activation drives many pediatric low-grade gliomas.
Can it be targeted?
Yes — by BRAF and MEK inhibitor drugs.
Bottom line
The MAPK/ERK pathway is a growth-signaling system whose abnormal activation drives many pediatric low-grade gliomas and can be targeted by BRAF and MEK inhibitors.
Browse all 265 Glioma definitions
Read the Glioma patient guides
Not sure which page you need? Put words to it with the symptom navigator